Compare ZUMZ & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZUMZ | VCRE |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.2M | 316.4M |
| IPO Year | 2005 | 2026 |
| Metric | ZUMZ | VCRE |
|---|---|---|
| Price | $13.95 | $10.32 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 304.8K | 11.3K |
| Earning Date | 06-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $929,057,000.00 | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $13.07 | $10.03 |
| 52 Week High | $31.70 | $13.15 |
| Indicator | ZUMZ | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 35.15 |
| Support Level | N/A | N/A |
| Resistance Level | $18.87 | $13.00 |
| Average True Range (ATR) | 0.68 | 0.58 |
| MACD | -0.35 | -0.11 |
| Stochastic Oscillator | 16.90 | 9.91 |
Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.